Angela Bonura

Angela Bonura

Auto-generated profile, based on publicly available information

Angela Bonura

Istituto di Biomedicina ed Immunologia Molecolare "Alberto Monroy" del Consiglio Nazionale delle Ricerche, Via Ugo La Malfa 153, Palermo, Italy

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2003 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
PCPaolo Colombo
Paolo Colombo
ABAngela Bonura
Angela Bonura
MCMaria Assunta Costa
Maria Assunta Costa
VIVincenzo Izzo
Vincenzo Izzo
RPRosa Passantino
Rosa Passantino
DGDomenico Geraci
Domenico Geraci
Parietaria is a genus of dicotyledonous weeds of the Urticaceae family including several species and its pollen grain is one of the most important allergenic sources in the Mediterranean area. Species belonging to this genus induce IgE responses in approximately 10 million people. Identification of allergens by means of independent strategies suggest that the allergens of the two more common species, Parietaria judaica and Parietaria officinalis, show molecular weights ranging between 10 and 14 kD and that the allergens of the two extracts are highly cross-reactive. Biochemical analysis and molecular cloning allowed the isolation and immunological characterization of the two major allergens of the P. judaica pollen, Par j 1 and Par j 2. Sequence comparison suggests that the P j major allergens of P. judaica belong to the nonspecific lipid transfer protein family, and three-dimensional modeling by homology has revealed that both proteins present a very conserved structural motif composed of four α-helices. Immunological analysis has shown that Par j 1 and Par j 2 are able to bind most of the P. judaica-specific IgE and some of their IgE determinants have been mapped. Recombinant Par j 1 and Par j 2 allergens have been shown to possess immunological properties equivalent to their natural counterpart and their availability represents a fundamental tool for the diagnosis and therapy of Parietaria pollen allergy.

1 September 2001 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
ABAngela Bonura
Angela Bonura
SASaverio Amoroso
Saverio Amoroso
GLGiovanni Locorotondo
Giovanni Locorotondo
GFGabriella Di Felice
Gabriella Di Felice
RTRaffaella Tinghino
Raffaella Tinghino
PCPaolo Colombo
Paolo Colombo
Background: Par j 1 represents a major allergenic component of Parietaria judaica (Pj) pollen, since it is able to induce an immunoglobulin E (IgE) response in 95% of Pj-allergic patients. It belongs to the non-specific lipid transfer protein family, sharing with them a common three-dimensional structure. Methods: Disulphide bond variants of the recombinant Par j 1 (rPar j 1) allergen were generated by site-directed mutagenesis, and the immunological activity of rPar j 1 and its conformational mutants was compared with the use of the skin prick test (SPT). The ability to bind IgE antibodies was evaluated by Western blot, ELISA and ELISA inhibition. T cell reactivity was measured by peripheral blood mononuclear cell proliferation assay. Results: The disruption of Cys14–Cys29 and Cys30–Cys75 bridging (PjA mutant) caused the loss of the majority of specific IgE-binding activity. Additional disruption of the Cys4–Cys52 bridge (PjC mutant) and the latter Cys50–Cys91 bridge (PjD mutant) led to the abolition of IgE-binding activity. On the SPT, PjB (lacking the Cys4–Cys52 and Cys50–Cys91 bridges) was still capable of triggering a type I hypersensitive reaction in 9 out of 10 patients, and PjA in 3 out of 10 patients, while PjC and PjD did not show any SPT reactivity. All the mutants preserved their T cell reactivity. Conclusion: Recombinant hypoallergenic variants of the rPar j 1 allergen described herein may represent a useful tool for improved immunotherapy.

9 March 2004 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
AOAugusto Orlandi
Augusto Orlandi
FGF. Grasso
F. Grasso
SCS. Corinti
S. Corinti
MMM. Marinaro
M. Marinaro
ABA. Bonura
A. Bonura
GFGabriella Di Felice
Gabriella Di Felice

1 July 2009 in Molecular Immunology
Verified
Journal Article
Closed access
ABAngela Bonura
Angela Bonura
Aiti VizziniAiti Vizzini
Aiti Vizzini
GSGiuseppina Salerno
Giuseppina Salerno
NPNicolò Parrinello
Nicolò Parrinello
VLValeria Longo
Valeria Longo
PCPaolo Colombo
Paolo Colombo

11 May 2009 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
GMGiorgia Mastrangeli
Giorgia Mastrangeli
SCSilvia Corinti
Silvia Corinti
CBCinzia Butteroni
Cinzia Butteroni
CAClaudia Afferni
Claudia Afferni
ABAngela Bonura
Angela Bonura
GFGabriella Di Felice
Gabriella Di Felice
Background: The immunological mechanisms responsible for the immunomodulatory and anti-allergic effects of probiotic bacteria are still poorly defined. The combined effects of mixtures of different species of probiotic bacteria have been explored only in part. The present study describes the immunomodulatory activity of the VSL#3 probiotic preparation in in vitro and in vivo systems. Methods: The activation and cytokine production by in vitro probiotic-stimulated bone-marrow dendritic cells (BM-DCs) and spleen cells isolated from naïve or Par j 1-sensitized mice were investigated. Mice were intranasally administered a sonicate preparation of VSL#3 before immunization with rPar j 1. Serum antibody levels and cytokine expression in the lung were determined. Results: Both live and sonicated VSL#3 preparations induced maturation and cytokine production by BM-DCs. Cytokine production by spleen cells from naïve or Par j 1-sensitized mice was modulated by the probiotic preparations towards a Treg/Th0 profile, characterized by increased IL-10 and IFN-γ production. In vivo prophylactic treatment with VSL#3 induced a significant reduction of serum specific IgG1. At lung level, VSL#3 pre-treatment remarkably reduced IL-13 and IL-4 mRNA expression and increased IL-10 expression. Conclusions: The VSL#3 preparations have not only the capacity to bias primary immune responses towards a Treg/Th0-type profile, but also to modify in the same way the functional characteristics of established in vitro Th2 responses. In vivo studies on a mouse model of Par j 1 sensitization indicate that the prophylactic intranasal treatment with probiotic bacteria is able to modulate the development of Th2-biased responses.

1 January 1990 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
MCMarta Di Carlo
Marta Di Carlo
GMGiovanna Montana
Giovanna Montana
ABAngela Bonura
Angela Bonura